

## Retraction: miR-211 suppresses hepatocellular carcinoma by downregulating SATB2

Guixing Jiang<sup>1</sup>, Yunfu Cui<sup>2</sup>, Xin Yu<sup>3</sup>, Zhengrong Wu<sup>1</sup>, Guoping Ding<sup>1</sup> and Liping Cao<sup>1</sup>

<sup>1</sup>Department of Hepatopancreatobiliary Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China

<sup>2</sup>Department of Hepatopancreatobiliary Surgery, Second Affiliated Hospital of Harbin Medical University, Harbin, China

<sup>3</sup>Department of Biochemistry and Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, Beijing, China

**Published:** April 24, 2026

**Copyright:** © 2026 Jiang et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has been retracted:** Oncotarget has completed its investigation of this paper. The review identified several instances of external image duplication and overlap:

- Figure 4D: The GAPDH blot is a duplicate of blot in Figure 4D of an earlier published unrelated paper [1].
- Figure 3B: The Transwell assay images were found in Figures 5A and 7C of earlier submitted and already retracted article [2].
- Figure 5A: The GAPDH blot was duplicated in Figure 4B of a retracted article [3].
- Figure 7E: The GAPDH blot was found in Figure 4A of article [4] and Figure 5B of article [5], which were submitted before the Oncotarget paper, as well as in Figure 4A of [6], Figure 5B of [7], and Figure 4D of [8].

Additionally, the cell lines SMMC-7721 and Hep-G2, used in this study as hepatocellular carcinoma cell lines, are known to be problematic [9–11]. These issues, combined with the identified duplications, raise significant concerns regarding the reliability of the data and conclusions. Consequently, the Editorial decision has been made to retract this paper. The authors were notified of this decision.

Original article: Oncotarget. 2015; 6:9457–9466. <https://doi.org/10.18632/oncotarget.3265>

### REFERENCES

1. Feng Y, Liu J, Kang Y, He Y, Liang B, Yang P, Yu Z. miR-19a acts as an oncogenic microRNA and is up-regulated in bladder cancer. *J Exp Clin Cancer Res.* 2014; 33:67. <https://doi.org/10.1186/PREACCEPT-9242556491295527>. [PubMed]
2. Liu T, Zhang X, Sha K, Liu X, Zhang L, Wang B. miR-709 up-regulated in hepatocellular carcinoma, promotes proliferation and invasion by targeting GPC5. *Cell Prolif.* 2015; 48:330–37. <https://doi.org/10.1111/cpr.12181>. [PubMed]. Retraction in: *Cell Prolif.* 2026; 59:e70151. <https://doi.org/10.1111/cpr.70151>. [PubMed]
3. Sun L, Wang Q, Gao X, Shi D, Mi S, Han Q. MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. *FEBS Lett.* 2015; 589:2791–96. <https://doi.org/10.1016/j.febslet.2015.08.007>. [PubMed]. Retraction in: *FEBS Lett.* 2022; 596:2851. <https://doi.org/10.1002/1873-3468.14513>. [PubMed]
4. Niu G, Li B, Sun L, An C. MicroRNA-153 inhibits osteosarcoma cells proliferation and invasion by targeting TGF-β2. *PLoS One.* 2015; 10:e0119225. <https://doi.org/10.1371/journal.pone.0119225>. [PubMed]. Retraction in: *PLoS One.* 2022; 17:e0269902. <https://doi.org/10.1371/journal.pone.0269902>. [PubMed]
5. Hu J, Lv G, Zhou S, Zhou Y, Nie B, Duan H, Zhang Y, Yuan X. The Downregulation of MiR-182 Is Associated with the Growth and Invasion of Osteosarcoma Cells through the Regulation of TIAM1 Expression. *PLoS One.* 2015; 10:e0121175. <https://doi.org/10.1371/journal.pone.0121175>. [PubMed]. Retraction in: *PLoS One.* 2023; 18:e0283115. <https://doi.org/10.1371/journal.pone.0283115>. [PubMed]
6. Jiang C, Shen F, Du J, Hu Z, Li X, Su J, Wang X, Huang X. MicroRNA-564 is downregulated in glioblastoma and inhibited proliferation and invasion of glioblastoma cells by targeting TGF-β1. *Oncotarget.* 2016; 7:56200–8. <https://doi.org/10.18632/oncotarget.8987>. [PubMed]. Retraction in: *Oncotarget.* 2025; 16:454–55. <https://doi.org/10.18632/oncotarget.28748>. [PubMed]

7. Guo X, Zhang J, Pang J, He S, Li G, Chong Y, Li C, Jiao Z, Zhang S, Shao M. MicroRNA-503 represses epithelial-mesenchymal transition and inhibits metastasis of osteosarcoma by targeting c-myc. *Tumour Biol.* 2016; 37:9181–87. <https://doi.org/10.1007/s13277-016-4797-4>. [PubMed]
8. Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, Feng F. By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. *Oncotarget.* 2015; 6:17559–69. <https://doi.org/10.18632/oncotarget.2755>. [PubMed]. Retraction in: *Oncotarget.* 2026; 17: 182–83. <https://doi.org/10.18632/oncotarget.28830>. [PubMed]
9. Ye F, Chen C, Qin J, Liu J, Zheng C. Genetic profiling reveals an alarming rate of cross-contamination among human cell lines used in China. *FASEB J.* 2015; 29:4268–72. <https://doi.org/10.1096/fj.14-266718>. [PubMed]
10. Rebouissou S, Zucman-Rossi J, Moreau R, Qiu Z, Hui L. Note of caution: Contaminations of hepatocellular cell lines. *J Hepatol.* 2017; 67:896–97. <https://doi.org/10.1016/j.jhep.2017.08.002>. [PubMed]
11. López-Terrada D, Cheung SW, Finegold MJ, Knowles BB. Hep G2 is a hepatoblastoma-derived cell line. *Hum Pathol.* 2009; 40:1512–15. <https://doi.org/10.1016/j.humpath.2009.07.003>. [PubMed]